Education
About Us
Working with TipRanks
Follow Us
Ginkgo Bioworks Holdings (DNA)
NYSE:DNA
DNA Stock Chart & Stats
$11.30
-$0.35(-3.13%)
At close: 4:00 PM EST
$11.30
-$0.35(-3.13%)
Day’s Range― - ―
52-Week Range$5.00 - $17.58
Previous CloseN/A
Volume618.97K
Average Volume (3M)1.59M
Market Cap
$686.13M
Enterprise ValueN/A
Total Cash (Recent Filing)$473.69M
Total Debt (Recent Filing)$428.83M
Price to Earnings (P/E)―
Beta2.77
Next Earnings
Mar 04, 2026EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding47,089,600
10 Day Avg. Volume1,135,709
30 Day Avg. Volume1,586,844
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.71
Price to Sales (P/S)2.24
P/FCF Ratio-1.33
Enterprise Value/Market Cap0.00
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price Target
$11.50Price Target Upside1.77% Upside
Rating ConsensusModerate Sell
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cost ManagementGinkgo achieved its big cost-reduction target ahead of expectations, significantly reducing spending and making progress towards its goal of achieving positive EBITDA.
Revenue GrowthManagement reaffirmed their FY25 Biosecurity guidance for $40M+ in revenues, which is considered achievable.
Strategic ExpansionThe company is expected to potentially benefit from continued expansion into AI Tools and automation offerings.
Bears Say
Industry ChallengesMacro uncertainties and a slowdown in the pharma industry are raising questions about growth into 2026.
Price Target AdjustmentThe price target for Ginkgo Bioworks Holdings has been adjusted downward to $14 from a previous $18.
Revenue OutlookThe company lowered its biosecurity revenue outlook for the year, citing greater uncertainty with its OUS business.
Ginkgo Bioworks Holdings News
DNA FAQ
What was Ginkgo Bioworks Holdings’s price range in the past 12 months?
Ginkgo Bioworks Holdings lowest stock price was $5.00 and its highest was $17.58 in the past 12 months.
What is Ginkgo Bioworks Holdings’s market cap?
Ginkgo Bioworks Holdings’s market cap is $686.13M.
When is Ginkgo Bioworks Holdings’s upcoming earnings report date?
Ginkgo Bioworks Holdings’s upcoming earnings report date is Mar 04, 2026 which is in 116 days.
How were Ginkgo Bioworks Holdings’s earnings last quarter?
Ginkgo Bioworks Holdings released its earnings results on Nov 06, 2025. The company reported -$1.45 earnings per share for the quarter, missing the consensus estimate of -$1.241 by -$0.209.
Is Ginkgo Bioworks Holdings overvalued?
According to Wall Street analysts Ginkgo Bioworks Holdings’s price is currently Undervalued.
Does Ginkgo Bioworks Holdings pay dividends?
Ginkgo Bioworks Holdings does not currently pay dividends.
What is Ginkgo Bioworks Holdings’s EPS estimate?
Ginkgo Bioworks Holdings’s EPS estimate is -1.36.
How many shares outstanding does Ginkgo Bioworks Holdings have?
Ginkgo Bioworks Holdings has 47,089,600 shares outstanding.
What happened to Ginkgo Bioworks Holdings’s price movement after its last earnings report?
Ginkgo Bioworks Holdings reported an EPS of -$1.45 in its last earnings report, missing expectations of -$1.241. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Ginkgo Bioworks Holdings?
Currently, no hedge funds are holding shares in DNA
Ginkgo Bioworks Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$11.50 (1.77% Upside)
$11.50 (1.77% Upside)
Blogger Sentiment
Neutral
DNA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 38.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $219.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.7%
Last 30 Days ▼ 1.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.98%
12-Months-Change
Fundamentals
Return on Equity
-43.59%
Trailing 12-Months
Asset Growth
-24.26%
Trailing 12-Months
Company Description
Ginkgo Bioworks Holdings
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
DNA Company Deck
DNA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in cost reductions and cash position, as well as strategic expansions and partnerships. However, these were offset by notable challenges in revenue declines and increased operating losses in the Cell Engineering segment. While the company is making strategic moves to position itself for future growth, the current financial metrics present a mixed picture.View all DNA earnings summariesDNA Revenue Breakdown
57.08% Cell Engineering
42.92% Biosecurity
DNA Stock 12 Month Forecast
Average Price Target
$11.50
▲(1.77% Upside)
Technical Analysis
Sana Biotechnology
―
Tourmaline Bio
―
Erasca
―
Rapport Therapeutics, Inc.
―
Maze Therapeutics, Inc.
―
Ownership Overview
1.02% Insiders
16.26% Mutual Funds
0.03% Other Institutional Investors
68.62% Public Companies and Individual Investors